Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

Company: BerGenBio Date: 2025-03-26 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

# BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

The article identifies promising survival results in relapsed/refractory AML  

patients  

  

warranting further study  

  

Bergen, Norway - 26 March 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage  

biopharmaceutical company developing novel, selective AXL inhibitors for severe  

unmet medical needs, today announces the publication of a peer-reviewed article  

entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine  

in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the  

journalNature Communications.  

  

This article is accessible here: www.nature.com/articles/s41467-025-58179-6.pdf  

  

The article highlights results in 36 patients treated with a combination of  

BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low  

\-dose cytarabine(LDAC) chemotherapy. Overall, patients who received the  

combination had an overall survival of 7.8 months, substantially longer than  

that expected in this difficult-to-treat patient population.  

  

The lead investigator of the study, Professor Sonja Loges, MD, PhD. of the  

German Cancer Research Center (DKFZ), Heidelberg, Germany stated, "Following  

first line treatment of AML, most patients will relapse, and beyond first line  

the prognosis of older patients with relapsed or refractory AML, the population  

studied in BGBC003 is particularly poor. With other treatment approaches, the  

current overall survival of R/R AML patients is believed to be approximately 2.9  

\-4 months.  The authors of this article believe that the BGBC003 results in this  

population warrant further study."  

  

Olav Hellebo, CEO of BerGenBio commented "Our BGBC003 study evaluated  

bemcentinib in relapsed/refractory (R/R) AML patients who have limited effective  

treatment options today.  The presence of AXL is a poor prognostic factor in  

this population and AXL is believed to promote chemotherapy resistance and  

decreased antitumor immune response.  We believe, as a highly selective AXL  

inhibitor, bemcentinib holds promise as a treatment for these patients with  

extremely high unmet medical needs."  

  

Contacts  

  

Olav Hellebo, BerGenBio ASA  

  

ir@bergenbio.com  

  

Rune Skeie, CFO, BerGenBio ASA  

  

rune.skeie@bergenbio.com  

  

Investor Relations / Media Relations  

  

Jan Lilleby  

  

jl@lillebyfrisch.no  

  

About BerGenBio ASA  

  

BerGenBio is a clinical-stage biopharmaceutical company focused on developing  

transformative drugs targeting AXL as a potential cornerstone of therapy for  

aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with  

a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange  

(ticker: BGBIO). For more information, visit?www.bergenbio.com.  

  

Forward looking statements  

  

This announcement may contain forward-looking statements, which as such are not  

historical facts, but are based upon various assumptions, many of which are  

based, in turn, upon further assumptions. These assumptions are inherently  

subject to significant known and unknown risks, uncertainties, and other  

important factors. Such risks, uncertainties, contingencies and other important  

factors could cause actual events to differ materially from the expectations  

expressed or implied in this announcement by such forward-looking statements.  

  

This information is subject to the disclosure requirements pursuant to section 5  

\-12 of the Norwegian Securities Trading Act.

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.